SCHEMBL7105161

SCHEMBL7105161

C[C@H](NOCCc1ccccc1)C(=O)OP(=O)(O)Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
CA9 Q16790 1/20 0.38
TSHR P16473 3/20 0.37
POLB P06746 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP1A2 P05177 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207832 0.90 MEN1 (0.41) MEN1KMT2ASMN1; SMN2HTTHPGD
SCHEMBL7207845 0.87 MEN1 (0.40) MEN1KMT2ASMN1; SMN2HTTHPGD
SCHEMBL4282703 0.87 CA1 (0.46) CA1CA2MMP2CA9TSHR
SCHEMBL4282571 0.87 CA1 (0.46) CA1CA2MMP2CA9TSHR
SCHEMBL27536452 0.87 CA1 (0.46) CA1CA2MMP2CA9TSHR
SCHEMBL7026839 0.85 ELANE (0.41) MEN1KMT2ASMN1; SMN2HTTHPGD
SCHEMBL28899399 0.79 ACP3 (0.47) MEN1KMT2APOLBMAPTL3MBTL1
SCHEMBL16348702 0.79 ACP3 (0.47) MEN1KMT2APOLBMAPTL3MBTL1
SCHEMBL12477586 0.78
SCHEMBL1287355 0.77 CA1 (0.47) MEN1KMT2ACA1CA2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6638919-B2 Aids therapy UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2003-10-28 US disclosed
EP-1117669-B1 ANTIVIRAL PURINE DERIVATIVES UNIV CARDIFF (GB) 2003-01-29 EP disclosed
US-20010031745-A1 Antiviral purine derivatives UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2001-10-18 US disclosed
EP-1117669-A1 ANTIVIRAL PURINE DERIVATIVES UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) 2001-07-25 EP disclosed
WO-2000018775-A1 ANTIVIRAL PURINE DERIVATIVES UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031745-A1 Antiviral purine derivatives PNP, TYMP, MTAP MEN1 1563/4885KMT2A 3808/4885SMN1; SMN2 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.